Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 22Liraglutide literatureLancet (London, England)Top journal2026

Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity.

Not reported in abstract.

Read at Lancet (London, England)Add to compare

Where it sits

this study against the rest of the liraglutide corpus
6
Preclinical · this one
10
Observational
0
Open-label
2
Randomised
4
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Liraglutide corpus

BEmerging Therapeutic Strategies for Infantile Obesity: A Narrative Reviewbiorxiv-preprint · 2026 · n=4331 · 1.71 kg/m² BMI reduction with medication plus behavioral treatment vs behavioral treatment alone, n=4331.reviewBPrevention of new-onset chronic kidney disease with renin-angiotensin system blockers in type 2 diabetes with preserved kidney function.Renal failure · 2026 · n=4725 · HR 0.72; 95% CI 0.60-0.86 for new-onset CKD with ACEI/ARB therapy.HumanBSGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.Journal of affective disorders · 2026 · n=5114 · aHR 0.87, 95% CI 0.71-1.06 for KRT risk in full cohort.HumanCImportance of antibody validation in detecting cell cycle regulatory protein p16 <sup><b>INK4A</b></sup> by immunohistochemistry on pancreas tissue.Islets · 2026 · Not reported in abstract.In vitroBAdherence to the Mediterranean diet and its effects on the onset and progression of diabetic nephropathy: a systematic review.Renal failure · 2026 · 21% to 86% reduction in risk of DN with higher MD adherence.reviewDCompounded GLP-1 Drugs Remain Prevalent After Drug Shortage.JAMA · 2026